Beranda › Kanker Laring › North Dakota
Uji klinis Kanker Laring di North Dakota
5 studi untuk Kanker Laring mencari peserta di lokasi di North Dakota.
Kota di North Dakota
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Sanford Bismarck Medical Center, Bismarck
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06589804BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Sanford Bismarck Medical Center, Bismarck
- Essentia Health Cancer Center-South University Clinic, Fargo
- Sanford Broadway Medical Center, Fargo
- dan 2 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05136196Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Sanford Bismarck Medical Center, Bismarck
- Essentia Health Cancer Center-South University Clinic, Fargo
- Sanford South University Medical Center, Fargo
- dan 3 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT02734537Integrated Cancer Repository for Cancer Research
- Essentia Health, Fargo
- Trinity Hospital Cancer Care Center, Minot
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Fargo
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.